TCS 46b

TargetMol
Product Code: TAR-T23449
Supplier: TargetMol
CodeSizePrice
TAR-T23449-1mg1mg£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23449-5mg5mg£158.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23449-10mg10mg£212.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23449-25mg25mg£369.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23449-50mg50mg£550.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23449-100mg100mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23449-500mg500mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
TCS 46b is a NR1A/NR2B NMDA receptor antagonist with oral activity.
CAS:
302799-86-6
Formula:
C22H23N3O
Molecular Weight:
345.446
Pathway:
Neuroscience
Purity:
0.9981
SMILES:
O=c1[nH]c2ccc(cc2[nH]1)C#CCN1CCC(Cc2ccccc2)CC1
Target:
NMDAR

References

1. Nikam SS, Meltzer LT. NR2B selective NMDA receptor antagonists. Curr Pharm Des. 2002;8(10):845-55. doi: 10.2174/1381612024607072. PMID: 11945135. 2. Wright JL, Gregory TF, Kesten SR, Boxer PA, Serpa KA, Meltzer LT, Wise LD, Espitia SA, Konkoy CS, Whittemore ER, Woodward RM. Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(heteroarylalkynyl)-4-benzylpiperidines. J Med Chem. 2000 Sep 7;43(18):3408-19. doi: 10.1021/jm000023o. PMID: 10978188. 3. Dischino D D , Gribkoff V K , Hewawasam P , et al. Synthesis of 3H and 14C labeled (S)?3?(5?chloro?2?methoxyphenyl)?1,3?dihydro?3?fluoro?6?(trifluoromethyl)?2H?indol?2?one, maxipost. An agent for post?stroke neuroprotection[J]. Journal of Labelled Compounds and Radiopharmaceuticals, 2003, 46(2):139-149.